ASMB

NASDAQ Healthcare

Assembly Biosciences, Inc. - Common Stock

Biotechnology

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

๐Ÿ“Š Market Data
Price$24.49
Volume276,588
Market Cap485.32M
RSI (14-Day)27.0 Oversold
200-Day MA$29.02
50-Day MA$28.43
52-Week High$39.71
52-Week Low$15.12
P/E Ratio306.12
Forward P/E-9.04
Price / Book1.96
๐ŸŽฏ Investment Strategy Scores

ASMB scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 31/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 25/100โ–ฒ +7
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 92/100โ–ฒ +8
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 5/100โ–ผ -9
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (92/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (5/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find ASMB in your text

Paste any article, transcript, or post โ€” the tool will extract ASMB and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.